Pharma firms pile pressure on the UK as Trump's drug pricing order looms
A number of global pharma firms have pulled or paused U.K. investment plans amid waning government support and drug pricing talks.
You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.